On November 16, PEGBIO CO-B rose 7.08% in Regular Trading, trading at HK$3.38, with turnover of HK$50.10 million.
The move followed the company’s disclosure that its core product, Paidakang, or vebinatide injection, was included in the latest National Reimbursement Drug List, a milestone viewed by the market as supportive of commercialization.
The company said the drug is its first commercialized innovative therapy and has been approved for blood glucose control in adults with type 2 diabetes. Reported differentiating features include once-weekly dosing, treatment initiation without dose titration, and direct use from the start of therapy. The reimbursement listing is expected to improve patient access and support the transition from R&D to scaled commercialization. Earlier commercialization progress had already included first prescriptions and a milestone payment tied to launch execution.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments